Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN

Travere Therapeutics, Inc.

2022-FY EPS reported -$4.37 revenue$212,018,000

Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.
Net loss $65.8M ($1.03 per share) in Q4 2022 vs $51.6M ($0.84) in Q4 2021; full year loss $278.5M.
Cash and marketable securities $450.2M as of Dec 31, 2022.
FDA granted accelerated approval of FILSPARI (sparsentan) for IgAN on Feb 17, 2023; commercial launch expected week of Feb 27.
Topline data from DUPLEX Study (FSGS) expected Q2 2023; EMA decision on sparsentan for IgAN expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $55.9 million, net income ($65.8 million, or $1.03 per basic share).

Period: fourth quarter and full year ended December 31, 2022
Revenue: $55.9 million
Net income: ($65.8 million, or $1.03 per basic share)
Result: reported results

Exact text from the filing

confirmatory endpoints in the ongoing Phase 3 PROTECT Study of sparsentan in IgAN expected in the fourth quarter of 2023 • Total revenue for the fourth quarter of 2022 was $55.9 million, consisting of $52.3 million in net product sales and $3.5 million in licensing and collaboration revenue • Total revenue for the full year 2022 was $212.0 million, consisting of

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.